Production (Stage)
Arrowhead Pharmaceuticals, Inc.
ARWR
$15.13
-$0.26-1.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 21,608.36% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 21,608.36% | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 21,608.36% | -- | |||
| SG&A Expenses | 17.54% | -5.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.47% | 1.05% | |||
| Operating Income | 336.17% | 0.49% | |||
| Income Before Tax | 311.07% | -1.34% | |||
| Income Tax Expenses | 1,601.94% | -81.14% | |||
| Earnings from Continuing Operations | 309.95% | -1.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 21.05% | -24.04% | |||
| Net Income | 314.02% | -1.49% | |||
| EBIT | 336.17% | 0.49% | |||
| EBITDA | 347.98% | 0.64% | |||
| EPS Basic | 300.35% | -1.09% | |||
| Normalized Basic EPS | 303.77% | -1.62% | |||
| EPS Diluted | 297.84% | -1.36% | |||
| Normalized Diluted EPS | 302.07% | -1.62% | |||
| Average Basic Shares Outstanding | 6.82% | 0.40% | |||
| Average Diluted Shares Outstanding | 7.72% | 0.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||